Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited (DSKYF ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...